Table 1 Characteristics of the primary breast cancer patient population based on the success of PDX engraftment
From: Factors associated with engraftment success of patient-derived xenografts of breast cancer
Variable | All (n = 353) | NAC group (n = 156) | ||||
|---|---|---|---|---|---|---|
Failure (n = 294) | Success (n = 59) | p-value* | Failure (n = 109) | Success (n = 47) | p-value* | |
Age | 50.9 ± 12.2 | 45.8 ± 11.0 | 0.003 | 50.4 ± 10.7 | 45.2 ± 11.0 | 0.007 |
Subtype | < 0.001 | < 0.001 | ||||
HER2 + | 20 (6.8%) | 1 (1.7%) | 8 (7.3%) | 1 (2.1%) | ||
HR + | 147 (50.0%) | 5 (8.5%) | 48 (44.0%) | 4 (8.5%) | ||
HR + /HER2 + | 32 (10.9%) | 1 (1.7%) | 16 (14.7%) | 1 (2.1%) | ||
TNBC | 95 (32.3%) | 52 (88.1%) | 37 (33.9%) | 41 (87.2%) | ||
Ki-67LI (%) | 39.0 ± 29.1 | 73.2 ± 14.9 | < 0.001 | 33.9 ± 32.3 | 74.0 ± 15.1 | < 0.001 |
NAC | < 0.001 | |||||
Yes | 109 (37.1%) | 47 (79.7%) | – | – | ||
No | 185 (62.9%) | 12 (20.3%) | – | – | ||
Diagnosis | 0.474 | 0.176 | ||||
IDC | 262 (89.1%) | 53 (89.8%) | 198(94.7%) | 43(91.5%) | ||
ILC | 7 (2.4%) | 0 (0.0%) | 2(0.96%) | 0(0.0%) | ||
Adenoid cystic carcinoma | 1 (0.3%) | 1 (1.7%) | 0(0.0%) | 0(0.0%) | ||
Invasive apocrine carcinoma | 1 (0.3%) | 0 (0.0%) | 0(0.0%) | 0(0.0%) | ||
Micropapillary carcinoma | 8 (2.7%) | 2 (3.4%) | 5(2.4%) | 2(4.3%) | ||
Metaplastic carcinoma | 8 (2.7%) | 3 (5.1%) | 1(0.5%) | 2(4.3%) | ||
Mucinous carcinoma | 7 (2.4%) | 0 (0.0%) | 3(1.4%) | 0(0.0%) | ||
Size (cm) | 3.3 ± 2.2 | 4.1 ± 2.6 | 0.019 | 4.3 ± 2.7 | 4.6 ± 2.7 | 0.542 |
LVI | 0.376 | 0.280 | ||||
Not identified | 163 (55.4%) | 37 (62.7%) | 53 (48.6%) | 28 (59.6%) | ||
Present | 131 (44.6%) | 22 (37.3%) | 56 (51.4%) | 19 (40.4%) | ||
Number of positive LNs | 2.7 ± 8.5 | 3.2 ± 7.3 | 0.646 | 5.6 ± 13.1 | 4.0 ± 8.0 | 0.336 |
TIL (%) | 11.0 ± 17.9 | 9.3 ± 13.6 | 0.43 | 4.8 ± 10.3 | 6.6 ± 9.6 | 0.303 |
HG | < 0.001 | < 0.001 | ||||
2 | 153 (52.0%) | 5 (8.5%) | 55 (50.5%) | 4 (8.5%) | ||
3 | 141 (48.0%) | 54 (91.5%) | 54 (49.5%) | 43 (91.5%) | ||
pT | 0.099 | 0.433 | ||||
1 | 74 (25.2%) | 10 (16.9%) | 16 (14.7%) | 5 (10.6%) | ||
2 | 170 (57.8%) | 36 (61.0%) | 57 (52.3%) | 29 (61.7%) | ||
3 | 47 (16.0%) | 10 (16.9%) | 33 (30.3%) | 10 (21.3%) | ||
4 | 3 (1.0%) | 3 (5.1%) | 3 (2.8%) | 3 (6.4%) | ||
pN | 0.396 | 0.093 | ||||
0 | 154 (52.4%) | 35 (59.3%) | 34 (31.2%) | 25 (53.2%) | ||
1 | 85 (28.9%) | 12 (20.3%) | 35 (32.1%) | 10 (21.3%) | ||
2 | 32 (10.9%) | 5 (8.5%) | 23 (21.1%) | 5 (10.6%) | ||
3 | 23 (7.8%) | 7 (11.9%) | 17 (15.6%) | 7 (14.9%) | ||
M | 1.000 | 1.000 | ||||
0 | 291 (99.0%) | 58 (98.3%) | 106 (97.2%) | 46 (97.9%) | ||
1 | 3 (1.0%) | 1 (1.7%) | 3 (2.8%) | 1 (2.1%) | ||
AJCC stage | 0.55 | 0.213 | ||||
I | 55 (18.7%) | 7 (11.9%) | 12 (11.0%) | 4 (8.5%) | ||
II | 162 (55.1%) | 35 (59.3%) | 43 (39.4%) | 27 (57.4%) | ||
III | 75 (25.5%) | 16 (27.1%) | 51 (46.8%) | 15 (31.9%) | ||
IV | 2 (0.7%) | 1 (1.7%) | 3 (2.8%) | 1 (2.1%) | ||
Miller Payne grade | < 0.001 | |||||
1 | - | - | 19 (17.4%) | 26 (55.3%) | ||
2 | - | - | 39 (35.8%) | 10 (21.3%) | ||
3 | - | - | 46 (42.2%) | 11 (23.4%) | ||
4 | - | - | 5 (4.6%) | 0 (0.0%) | ||
RCB score | - | - | 3.1 ± 1.0 | 3.2 ± 1.2 | 0.659 | |
RCB class | 0.052 | |||||
I | - | - | 4 (3.7%) | 0 (0.0%) | ||
II | - | - | 44 (40.4%) | 28 (59.6%) | ||
III | - | - | 61 (56.0%) | 19 (40.4%) | ||